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Abstract
Conjugation with polyethylene glycol (PEG), known as PEGylation, has been widely used to improve the bioavailability of proteins
and low molecular weight drugs. The covalent conjugation of PEG to the carbohydrate moiety of a protein has been mainly used to
enhance the pharmacokinetic properties of the attached protein while yielding a more defined product. Thus, glycoPEGylation was
successfully applied to the introduction of a PEGylated sialic acid to a preexisting or enzymatically linked glycan in a protein.
Carbohydrates are now recognized as playing an important role in host–pathogen interactions in protozoal, bacterial and viral infec-
tions and are consequently candidates for chemotherapy. The short in vivo half-life of low molecular weight glycans hampered their
use but methods for the covalent attachment of PEG have been less exploited. In this review, information on the preparation and
application of PEG-carbohydrates, in particular multiarm PEGylation, is presented.
Introduction
In recent years, the modification of biotherapeutics by covalent
conjugation with polyethyleneglycol (PEG) known as PEGyla-
tion has emerged as an effective strategy to improve the thera-
peutic potential of drugs through less frequent dosing [1-3].
PEG is a biologically inert, non-immnunogenic linear polyether
diol that confers proteins greater solubility in aqueous and
organic media. It is being used in pharmaceutical areas not only
to enhance water solubility and reduce immunogenicity but also
to increase in vivo circulation half-life by preventing enzymatic
degradation and renal clearance [4]. Numerous examples of
bioconjugation with PEG have been reported including, among
others, proteins located in adenovirus coat for vaccine develop-
ment [5], antibodies or antibody fragments to prolong their
circulating half-lives in vivo [6] and selective alkylation and
acylation of amino groups in a somatostatin analog using two
different PEG reagents [7]. Also, PEGylation of low molecular
weight drugs in order to increase solubility [8], prolong the in
vivo action [9] or for targeting drug delivery [10] has been
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Figure 1: Types of PEG utilized for derivatization of drugs and peptides.
described. The potent anti-inflammatory drug dexamethasone
was coupled to a multifunctional PEG, prepared by a click reac-
tion, for treatment of rheumatoid arthritis [11]. A heterobifunc-
tional PEG has been conjugated with both paclitaxel, a potent
anticancer drug, and alendronate, a bone-targeting biphospho-
nate, in order to obtain strong bone tropism and fast drug
release [12]. An enzymatic method using a microbial transgluta-
minase was described for PEGylation of human growth
hormone [13].
Glycans have been recognized as immunodominant epitopes in
antigenic glycoconjugates [14]. Carbohydrates participate
in molecular recognition events such as host–pathogen
interactions, responsible for mammal infections, and are
candidates for chemotherapy [15]. Moreover, synthesis of
multivalent carbohydrate ligands provide higher affinity for
receptors as described for Shiga-like toxins [16] and other
systems [17].
Several excellent reviews have been published on PEGylation
of proteins, including PEG-drugs in the market [2,18-21].
However, PEGylation of carbohydrate molecules has been less
exploited and studies have been focused on polysaccharides or
on carbohydrates linked to proteins. A review dedicated to
PEGylated chitosan derivatives has been published [22].
In the present review we present different approaches used for
modification of glycans by covalent conjugation with PEG
reagents, in particular with multiarm PEGs, with the aim to
increase the loading of the active sugar. Multivalent glycomole-
cules have proven to mediate or inhibit a variety of biological or
pathological processes [17,23].
Review
Polyethylene glycol (PEG) derivatives
Polyethyleneglycol is an amphiphilic polymer consisting of
repeating units of ethylene oxide which may be assembled in
linear or branched structures to give a range of PEGs with
different shapes and molecular weights (Figure 1). PEG must be
activated for further conjugation by substitution of terminal OH
by a functional group that could react with an appropriate site in
the molecule to be conjugated, maintaining its biological
activity. Examples of activated PEGs are shown in Figure 2.
Multiarm PEGs have the advantage of presenting several sites
for conjugation and, in the higher MW conjugates, the arms are
far away enough from each other to allow independent inter-
action with the target site.
GlycoPEGylation of proteins
PEGylation of proteins is usually performed on the ε-amine
group of lysine or on the unprotected α-amino of the N-terminal
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Figure 2: Activated PEG derivatives for conjugation.
amino acid using N-hydroxysuccinimidyl (NHS) activated
PEGs or aldehyde PEGs. This conjugation leads to heteroge-
neous products, depending on the number of lysine residues in
the molecule. Random PEGylation may have undesired steric
effects, shielding active sites in the protein or disrupting its
tertiary structure [24].
PEGylation may be also directed to the side-chain amide
nitrogen of Asn. In order to improve the pharmacokinetic prop-
erties of a protein, N-PEGylation may be used additively to
N-glycosylation since both modifications stabilize the protein
by different mechanisms [25]. Also, glutamine residues on
intact or chimeric proteins can be combined with alkylamino-
PEG derivatives by the use of a transglutaminase [26].
Several methods have been developed for site-directed PEGyla-
tion. One of the most popular involves the reaction of the thiol
group in one or two cysteine residues with appropriate PEG
derivatives. The cysteine could be originally present in the
protein or introduced by mutagenesis [27,28]. The C-terminus
of the human growth hormone was PEGylated using a two-step
strategy in which a linker was first incorporated by a
carboxypeptidase-catalyzed transpeptidation and then used for
the ligation of the PEG moiety [29]. A more specific and irre-
versible attachment of a single PEG molecule has been
achieved by the use of a [3 + 2] cycloaddition reaction of an
alkyne-bearing PEG reagent and an azide-functionalized tyro-
sine residue genetically incorporated on human superoxide
dismutase-1 [30].
GlycoPEGylation, targeting carbohydrate sites, was conceived
to produce a more homogeneous product with lower steric
effects [31]. The strategy is based on the finding that certain
PEGylated nucleotide-sugars are effectively transferred to a
glycan acceptor by the corresponding glycosyltransferase.
A modified sialic acid PEGylated at the 5’-amino position in the
CMP nucleotide (CMP-SA-5-NHCOCH2NHPEG) can be trans-
ferred to a glycan acceptor in a glycoprotein by a sialyltrans-
ferase [32,33]. A chemoenzymatic method for its preparation is
shown in Scheme 1. It is based on the coupling of Fmoc-glycyl-
mannosamine with pyruvate catalized by SA-aldolase to afford
the N-protected sialic acid. After reaction with CTP catalyzed
by CMP-sialic acid synthetase, the nucleotide is deprotected
and the free amine is utilized as a locus to PEG attachment.
The introduction of the PEGylated sialic acid into the glycopro-
tein takes place in two steps. First, an O-glycan is introduced
enzymatically and second, PEGylated sialic acid is transferred
to the glycan by a sialyltransferase. The serine or threonine
residues in the O-glycosylation sites serve as acceptors for
GalNAc using a convenient GalNAc transferase. This unit can
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Scheme 1: Chemoenzymatic method for the preparation of PEG-CMP-SA, adapted from [32,33].
Scheme 2: GlycoPEGylation by sequential in vitro, enzyme mediated, O-glycosylation followed by transfer of PEGylated sialic acid, adapted from
[31].
be galactosylated by a galactosyltransferase and both, the
monosaccharide and the disaccharide, may be acceptors for
PEG-sialic acid (Scheme 2). This technique was applied to
polypeptides used clinically and has the advantage that it is
easier to produce a recombinant protein using E. coli than to
obtain the glycosylated forms in eukaryotic cells [31].
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Scheme 3: Chemical glycation of a protein and PEGylation after periodate oxidation, adapted from [34].
Chemical glycation of a protein and PEGyla-
tion after periodate oxidation
A small glycan may be also introduced by chemical ligation to
an inaccessible aminoacid in a natural protein, like Cys34 in
human serum albumin. The glycan may be oxidized by perio-
date to afford aldehyde groups for selective multiple coupling
with a PEG hydrazide (PEG-Hz), as shown in Scheme 3 [34].
Analysis of the PEGylated species showed more than 90%
conversion, whereas less than 30% of the protein was
PEGylated by direct conjugation of the albumin with commer-
cial PEG-maleimide. The PEG-Hz may undergo pH controlled
hydrolysis which also depends on the number of units in the
linked sugar. Therefore release of the active protein may be
controlled by the structure of the sugar linker.
PEGylation of native glycosylated proteins
PEGylation of native glycoproteins may be performed by enzy-
matic or chemical modification of the glycan.
a) Enzymatic modification of the glycan
Enzymatic PEGylation of a glycoprotein can be performed in
three steps. First, the sialic acid is removed from the native
protein with a sialidase and subsequently Sia-PEG is transfered
to the uncovered terminal Gal units of the linked glycan taking
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advantage of the substrate promiscuity of the sialyltransferase
ST3GalIII [35,36]. The reaction is kinetically controlled and the
number of PEGs added depends on the reaction time. Finally,
the unreacted galactose residues should be blocked with sialic
acid to avoid hepatic clearance by the asialoglycoprotein
receptor. More recently, the same group modified genetically
the coagulation factor VIII used to treat Hemophilia A, in order
to obtain a unique O-linked glycan for selective modification
with PEGylated sialic acid [37].
Alternatively, a terminal galactose may be oxidized at C-6 with
galactose oxidase to create the reactive site in the glycan that
could react with an activated PEG (Scheme 4A). As galactose is
usually substituted with sialic acid, the latter procedure was
applied before or after sialidase treatment [38].
Scheme 4: PEGylation of native glycosylated proteins after modifica-
tion of the glycan. (A) Enzymatic modification of the glycan; (B) Chem-
ical modification of the glycan, adapted from [38].
b) PEGylation after chemical modification of the
sugar chain of a glycoprotein
In this approach, a reactive group is created in the sugar of an
O- or N-linked glycan by a chemical modification. The terminal
residue of the N-linked carbohydrate in ricin A-chain has been
PEGylated by mild oxidation with periodate followed by reac-
tion with hydrazide-derivatized PEG [39]. The carbohydrate-
specifically modified ricin showed better pharmacokinetic prop-
erties than the peptide amino-PEGylated or the unmodified
ricin. The same technique was applied to glucose oxidase
(GOx), a glycosylated dimeric protein. In this case the hydra-
zone was further stabilized by reduction with cyanoborohy-
dride to afford a bioconjugate with retention of its activity as a
biosensor of glucose [40]. A similar strategy was applied to the
recombinant human thyroid-stimulating hormone (rhTSH,
Thyrogen). Terminal sialic acids were oxidized with sodium
periodate to generate aldehydes, which reacted with aminoxi-
PEGs (Scheme 4B). The use of this PEGylating agent, instead
of hydrazide-PEGs, generated a more stable oxime linkage with
the carbohydrate aldehydes. Similar to the other gonadotropins,
TSH is a glycosylated protein, and the role of the N-linked
oligosaccharides is well established. The effect of PEG size and
mono- vs multi-PEGylation was compared both in vitro and in
vivo. The best performing of the products, a 40-kDa mono-
PEGylated sialic acid-mediated conjugate, exhibited a 5-fold
lower affinity which was however compensated by a 23-fold
increase of circulation half-life [38].
PEGylation of low-molecular weight carbohydrates: Enzy-
matic esterification of two hydroxy methylene groups present in
pentofuranose derivatives with a PEG dimethyl ester yielded
sugar-PEG copolymers used for drug encapsulation. The carbo-
hydrate monomer was obtained by a multistep synthesis starting
from the easily available diacetone glucose (Scheme 5) [41].
Scheme 5: PEGylation of a pentofuranose derivative, adapted from
[41].
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Scheme 6: Galactosyl PEGylation of polystyrene nanoparticles, adapted from [42].
Figure 3: Mannosyl PEGylated polyethylenimine for delivery systems. (A) Mannose and PEG are independently linked to the PEI backbone;
(B) Mannose is attached to PEI via a PEG chain, adapted from [44].
Galactose has been PEGylated and introduced in the surface of
polystyrene nanoparticles in order to increase the interaction
with galactose receptors. p-Aminophenyl β-D-galactopyrano-
side was coupled with a bifunctional PEG activated on one end
with NHS for the combination with the aniline and a FMOC-
protected amino group on the other end. After deprotection,
the amine reacted with the carboxylic groups on the surface of
the nanoparticles (Scheme 6) [42]. A similar approach was
developed recently using poly(amidoamine) dendrimers for
selective delivery of chemotherapeutic agents into hepatic
cancer cells [43].
Mannose was also PEGylated in order to target drugs specifi-
cally to mannose receptors present in liver endothelial cells.
Mannosyl PEGylated polyethylenimine (PEI) conjugates were
synthesized either by direct coupling the mannose and the PEG
chain to the PEI backbone (Figure 3A) or by attaching the
mannose to PEI via a PEG chain spacer (Figure 3B). This
system was used to deliver small interfering RNA (siRNA) into
a murine macrophage cell line [44].
Mannose residues as their 2-aminoethyl glycosides were at-
tached by reductive amination to the surface of copolymer
Beilstein J. Org. Chem. 2014, 10, 1433–1444.
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Figure 4: PEGylated mannose derivatives, adapted from [45].
Scheme 7: PEGylation of lactose analogs [53].
micelles of PEG with poly-ε-caprolactone for targeting
dendritic cells and macrophages (Figure 4) [45]
Both mannose and galactose were attached to PEGylated
nanoparticles by click-chemistry between their propargyl glyco-
sides and a gold nanoparticles derivatized with an azide-func-
tionalized PEG [46]. Also, several unprotected carbohydrate
units of mannose, fucose or lactose, have been incorporated into
the surface of PEGylated dendritic polymers by means of click
chemistry. The larger dendrimer generations have demon-
strated an increased capacity to aggregate lectins [47].
Analogs of lactose have been reported as inhibitors of the
enzyme trans-sialidase (TcTS) [48], a virulence factor of
Trypanosoma cruzi [49-51]. It was shown that lactitol prevented
apoptosis caused by TcTS although it is rapidly eliminated from
the circulatory system [52]. With the aim to improve bioavail-
ability, PEGylation of lactose analogs was performed using two
approaches, both depending on the formation of an amide bond.
In one case the amino group was provided by the sugar and the
carboxylic acid by a NHS-activated PEG and in the other ap-
proach an amino-functionalized PEG reacted with lactobiono-
lactone (Scheme 7) [53].
Using linear PEGs of MW 5000 Da, no enhancement in the
permanence in blood was observed. However, improved
biovailability with retention of inhibition of TcTS was achieved
by PEGylation with multiarm PEGs of MW 40000 (Scheme 8)
[54]. In these complex conjugates, the degree of substitution is
determined by 1H NMR spectroscopy. The identification of
signals that disappear or are shifted when conjugation takes
place, together with the appearance of new signals due to the
sugar in well-separated regions of the spectrum are used to
confirm the extent of derivatization of the multiarm PEGs.
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Scheme 8: Conjugation of lactose analogs with dendritic PEGs [54].
PEGylation of polysaccharides: PEGylation of chitosan and
chitosan derivatives for pharmaceutical applications was
described [22]. Chitosan is the polysaccharide obtained from
the abundant chitin by alkali or enzymatic degradation. It
consists of a backbone of β-(1→4)-linked D-glucosamine units
with a variable degree of N-acetylation. The protonated amino
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groups of chitosan favor interaction with negatively charged
cellular surfaces. The amino groups of chitosan may be deriva-
tized with PEG chains, thus modifying the physicochemical
properties. Chitosan was first modified in the amino group of
the glucosamine units with a PEG-aldehyde to yield an imine
(Schiff base), which was subsequently reduced to PEG-g-
chitosan with sodium cyanoborohydride [55], allowing reten-
tion of net charge. PEGylation can also be accomplished by
condensation of the free amino groups with activated PEGs,
such as PEG-NHS or PEG-p-nitrophenyl carbonate, converting
the protonable amines into neutral amide or carbamate linkers.
Even though PEGylation of chitosan via the amino group is the
most commonly used method a number of examples of polysac-
charide derivatisation on the hydroxy groups have been
reported. Chitosan-O-poly(ethylene glycol) graft copolymers
were synthesized from N-phthaloylchitosan by etherification
with poly(ethylene glycol) monomethyl ether (mPEG) iodide
obtaining different degrees of O-substitution [56]. Several
strategies were designed to obtain regioselective PEGylation at
C-6 of the glucosamine unit [57]. Other methods of PEGylation
included, among others, free radical polymerization of C-6 of
the glucosamine residues with poly(ethylenglycol) acrylate
[58]; free-radical polymerization of C-1 of glucosamine with
mPEG [59] and 1,3-dipolar cycloaddition between the azide of
an N-azidated chitosan and mPEG derivatives containing a
triazolyl moiety [60].
Chitosan, partially substituted with lactobionic acid, bearing a
galactose, provides a ligand for the asialoglycoprotein receptor
of liver cells. Lactobionic acid formed an amide bond with the
glucosamine residue, and the non-substituded amino groups of
the galactosylated chitosan (GC) were further coupled with acti-
vated hydrophilic PEG to enhance its stability (Figure 5) [61].
Figure 5: PEGylated chitosan derivative, adapted from [61].
Bifunctional PEGs were used to introduce a bioactive molecule,
for instance biotine, coumarin, cholesterol or mannose into the
distal end of a PEG-chitosan complex (Figure 6) [62].
Figure 6: Chitosan/PEG functionalized with a mannose at the distal
end, adapted from [62].
Fructans have been PEGylated by reaction of hydroxy-acti-
vated polysaccharides with amino-terminated methoxy PEGs.
The reaction was applied to inulin [63] and to a polysaccharide
from Radix Ophiopogonis [64] for improving their pharmacoki-
netic properties. A similar activation of the sugar has been
previously applied to a dextran for further PEGylation. Hydro-
gels with supramolecular structures have been obtained by
inclusion complexation of the PEG grafted dextrans with
α-cyclodextrins. The unique thermoreversible sol-transition
properties of the gels were considered interesting for drug
delivery applications [65].
Conclusion
The advantage of PEGylation of glycan structures attached to
proteins is the possibility to restrict the reaction to the glyco-
sylated site affording a product with the benefits that PEGyla-
tion can impart without the loss of activity due to random multi-
step PEGylation of proteins. The examples presented in this
review on the PEGylation of carbohydrates show improvement
of some properties such as bioavailability of drugs, in particu-
lar enzyme inhibitors, or creation of polymers with encapsu-
lating properties for drugs. Apparently, the benefits of PEGyla-
tion were yet not extended to carbohydrate based drugs in the
market. In particular, multiarm PEGylation with more available
sites for glycan linking can be exploited for improvement of
interaction of carbohydrates with cell receptors. We hope that
this review on sugar PEGylation will provoke further studies on
the subject.
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